The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins

Experimental and Therapeutic Medicine

Volumn 6, Issue 2, 2013, Pages 299-304

  Chen, Xiaohui ^a   Yang, Chunmei ^b   Xu, Yanhua ^b   Zhou, Hui ^a   Liu, Hui ^b   Qian, Wenbin ^b  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute myeloid leukemia; Apoptosis; CYT997

Indexed keywords

CASPASE; CD123 ANTIGEN; LEXIBULIN; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REGULATOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84879670525     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1161     Document Type: Article

References (24)

1. Steffen B, Müller-Tidow C, Schwäble J, Berdel WE and Serve H: The molecular pathogenesis of acute myeloid leukemia. Crit Rev Oncol Hematol 56: 195-221, 2005.
2. Kuppens IE: Current state of the art of new tubulin inhibitors in the clinic. Curr Clin Pharmacol 1: 57-70, 2006.
3. Rovini A, Savry A, Braguer D and Carré M: Microtubule-targeted agents: when mitochondria become essential to chemotherapy. Biochim Biophys Acta 1807: 679-688, 2011.
4. Lysaght J, Verma NK, Maginn EN, et al: The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells. Int J Oncol 42: 239-246, 2013.
5. Petit I, Karajannis MA, Vincent L, et al: The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 111: 1951-1961, 2008.
6. Greene LM, Kelly L, Onnis V, et al: STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and-resistant Bcr-Abl-positive human chronic myeloid leukemia cells. J Pharmacol Exp Ther 321: 288-297, 2007.
7. Burns CJ, Harte MF, Bu X, et al: Discovery of CYT997: a structurally novel orally active microtubule targeting agent. Bioorg Med Chem Lett 19: 4639-4642, 2009.
8. Burns CJ, Fantino E, Phillips ID, et al: CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo. Mol Cancer Ther 8: 3036-3045, 2009.
9. Monaghan K, Khong T, Smith G and Spencer A: CYT997 causes apoptosis in human multiple myeloma. Invest New Drugs 29: 232-238, 2011.
10. Burns CJ, Fantino E, Powell AK, et al: The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo. J Pharmacol Exp Ther 339: 799-806, 2011.
11. Lickliter JD, Francesconi AB, Smith G, et al: Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. Br J Cancer 103: 597-606, 2010.
12. Burge M, Francesconi AB, Kotasek D, et al: Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent. Invest New Drugs 31: 126-135, 2013.
13. Jordan CT, Upchurch D, Szilvassy SJ, et al: The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14: 1777-1784, 2000.
14. Xu Q, Simpson SE, Scialla TJ, Bagg A and Carroll M: Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102: 972-980, 2003.
15. Nathwani SM, Butler S, Fayne D, et al: Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells. Cancer Chemother Pharmacol 66: 585-596, 2010.
16. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM and Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269, 1987.
17. Calligaris D, Verdier-Pinard P, Devred F, Villard C, Braguer D and Lafitte D: Microtubule targeting agents: from biophysics to proteomics. Cell Mol Life Sci 67: 1089-1104, 2010.
18. Martelli AM, Evangelisti C, Chiarini F and McCubrey JA: The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 1: 89-103, 2010.
19. Meng H, Jin Y, Liu H, et al: SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. J Hematol Oncol 6: 18, 2013.
20. Min YH, Eom JI, Cheong JW, et al: Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17: 995-997, 2003.
21. Récher C, Beyne-Rauzy O, Demur C, et al: Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105: 2527-2534, 2005.
22. Chapuis N, Tamburini J, Green AS, et al: Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16: 5424-5435, 2010.
23. Gavet O and Pines J: Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell 18: 533-543, 2010.
24. Lu LX, Domingo-Sananes MR, Huzarska M, Novak B and Gould KL: Multisite phosphoregulation of Cdc25 activity refines the mitotic entrance and exit switches. Proc Natl Acad Sci USA 109: 9899-8904, 2012.